NCT04907214View on ClinicalTrials.gov

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

December 8, 2023

Study Completion Date

December 8, 2023

Conditions
ObesityPre-diabetes
Interventions
DRUG

Empagliflozin 25 MG

Oral empagliflozin daily

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT04907214 - SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot | Biotech Hunter | Biotech Hunter